Equity Analysis /
United States of America

US : ChemoCentryx, Inc. - CCXI | First Take on PD-L1 Inhibitor CCX559 (Based on Data at ASCO)

    Contributors
    Timur Ivannikov
    Ryan Deschner
    CGS-CIMB
    6 June 2022
    Published by